Your Cart

Biotech Daily — Imagion Trial Review Backs Magsense for All Cancer MRI

Biotech Daily — Imagion Trial Review Backs Magsense for All Cancer MRI

“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners.

Imagion said that an independent, blinded review by a panel of expert breast cancer radiologists corroborated its previously reported findings that Magsense had the potential to detect tumor cells in lymph nodes by MRI.

The company said that each radiologist ascertained that the Magsense human epidermal growth factor receptor 2 (HER2) imaging agent “produced a change in image contrast and that the contrast in nodes highly suspicious for tumor was distinctly different from the magnetic resonance imaging (MRI) contrast seen in non-involved nodes.”

… continue reading the full column in the link below:

Read the article here.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.